Alan P. Venook, MD

Delve into Recent NCCN Guideline Updates for Hepatobiliary and CRC Management: With Alan P. Venook, MD

October 24th 2024

Hear Alan P. Venook, MD, discuss recent updates to the National Comprehensive Cancer Network (NCCN) Clinical Practice Guidelines for gastrointestinal cancers.

Dr. Venook on the Unmet Need Addressed by The GALAXY Trial Examining ctDNA in CRC

July 20th 2021

Alan P. Venook, MD, discusses the unmet need addressed by the GALAXY trial, part of the CIRCULATE-Japan project, which is examining circulating tumor DNA in patients with resectable colorectal cancer.

Dr. Venook Discusses Adjuvant Chemotherapy Duration in CRC

March 7th 2018

Alan P. Venook, MD, The Madden Family Distinguished Professor of Medical Oncology and Translational Research at the University of California, San Francisco Helen Diller Family Comprehensive Cancer Center, discusses adjuvant chemotherapy duration in colon cancer.

Dr. Venook Discusses the Role of Chemotherapy in Metastatic CRC

May 11th 2017

Alan P. Venook, MD, The Madden Family Distinguished Professor of Medical Oncology and Translational Research at the University of California, San Francisco Helen Diller Family Comprehensive Cancer Center, discusses the role of chemotherapy in metastatic colorectal cancer (CRC).

Dr. Venook on Advice for Oncologists Treating Patients With CRC

January 9th 2017

Alan P. Venook, MD, The Madden Family Distinguished Professor of Medical Oncology and Translational Research at the University of California, San Francisco Helen Diller Family Comprehensive Cancer Center, provides advice to community oncologists who are treating patients with colorectal cancer.

Dr. Venook on Important Factors for Treating Patients With CRC

December 20th 2016

Alan P. Venook, MD, The Madden Family Distinguished Professor of Medical Oncology and Translational Research at the University of California, San Francisco Helen Diller Family Comprehensive Cancer Center, discusses important factors for oncologists to consider when treating patients with colorectal cancer.

Dr. Venook on Immunotherapy Potential in Colorectal Cancer

December 15th 2016

Alan P. Venook, MD, The Madden Family Distinguished Professor of Medical Oncology and Translational Research at the University of California, San Francisco Helen Diller Family Comprehensive Cancer Center, discusses the potential that immunotherapy may have in the treatment of patients with colorectal cancer.

Dr. Venook on Distinguishing Molecular Features in CRC

November 10th 2016

Alan P. Venook, MD, The Madden Family Distinguished Professor of Medical Oncology and Translational Research at the University of California, San Francisco Helen Diller Family Comprehensive Cancer Center, discusses evolving treatment strategies for patients with colorectal cancer, with regards to molecular features such as sidedness.

Dr. Venook on Looking Ahead at Treatment for CRC

October 11th 2016

Alan P. Venook, MD, The Madden Family Distinguished Professor of Medical Oncology and Translational Research at the University of California, San Francisco Helen Diller Family Comprehensive Cancer Center, discusses future steps for treatment of patients with colorectal cancer.

Dr. Venook on Evolving Treatment Strategies in CRC

July 22nd 2016

Alan P. Venook, MD, The Madden Family Distinguished Professor of Medical Oncology and Translational Research at the University of California, San Francisco Helen Diller Family Comprehensive Cancer Center, discusses how treatment strategies have evolved for patients with colorectal cancer.

Dr. Venook Discusses the Approval of Ramucirumab Plus Paclitaxel

November 7th 2014

Alan P. Venook, MD, professor, Department of Medicine (Hematology/Oncology), University of California, San Francisco, discusses the approval of ramucirumab plus paclitaxel for gastric cancer

Dr. Venook Discusses the Future of Colorectal Cancer Treatment

September 15th 2014

Alan P. Venook, MD, professor, Department of Medicine (Hematology/Oncology), University of California, San Francisco, discusses the future of colorectal cancer treatment.

Dr. Venook Discusses the Results of the 80405 Trial

August 15th 2014

Alan P. Venook, MD, professor, Department of Medicine (Hematology/Oncology), University of California, San Francisco, discusses implications from the CALGB/SWOG 80405 trial of targeted therapies administered in colorectal cancer.

Dr. Venook Discusses Implications of the 80405 Study

June 28th 2014

Alan P. Venook, MD, a professor in the Department of Medicine (Hematology/Oncology) at the University of California, San Francisco, discusses implications from the CALGB/SWOG 80405 trial on the targeted therapies administered in colorectal cancer.

Dr. Venook on the Need for Collaboration in Research

October 14th 2013

Alan P. Venook, MD, a professor in the Department of Medicine (Hematology/Oncology) at the University of California, San Francisco, discusses the need for collaboration in cancer research.

Dr. Venook on Using Frailty Index & Geriatric Assessments

July 17th 2013

Alan P. Venook, MD, a professor in the Department of Medicine (Hematology/Oncology) at the University of California, San Francisco, discusses the importance of utilizing frailty index and geriatric assessments for patients with cancer.

Dr. Venook on Geographic Variations in Treatments

July 4th 2013

Alan P. Venook, MD, from the University of California, San Francisco, describes factors that contribute to the geographic variations seen in therapies utilized to treat cancer in the United States and Europe.